KALV: KalVista Pharma Company Value to Net Income

KalVista Corp - graphic logo of issuer KALV

KalVista Pharmaceuticals generates revenue by developing innovative oral therapies for rare immune pathologies. The company's average P/E reflects the asset's valuation trend, with the value of -6.80 serving as the current metric. The business moat is expanding due to patents for a unique drug, although operational stability remains heavily dependent on external clinical trial contractors.

KalVista Pharmaceuticals, Inc. (KALV) Price to Earnings Ratio: for the period 07/04/2022 - 06/21/2026

Analytical breakdowns for KalVista Corp (KALV)

- market capitalization information:
Comprehensive company analysis:KalVista Pharmaceuticals, Inc. KALV
Signature product of KalVista Pharmaceuticals Inc

The P/E ratio measures a business's market value relative to its net income, demonstrating how many years it will take for a company to recoup investments at current earning rates. By analyzing the P/E dynamics of KalVista Pharmaceuticals (KALV), an investor can assess the justification for the valuation premium currently priced in based on the anticipated FDA approval of sebetralstat and a potential acquisition by a major industry behemoth.

Key competitors

P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Market Cap to Earnings|AbCellera Biologics - P/E Multiple|tourmalinebio.com - Market Price to Net Income Ratio|Precigen (PGEN) - Price to Earnings Ratio|Pharming Group - Company Value to Net Income|Price to Earnings Ratio Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Price to Net Income Ratio|P/E Multiple ZBIO|P/E Multiple immunome.com (IMNM)|P/E Multiple GOSS (gossamerbio.com)|Septerna, Inc. (SEPN) - Market Cap to Earnings|PVLA - Price to Earnings Ratio|SVRA - P/E Multiple|Rigel Pharmaceuticals Inc (RIGL) - Price to Earnings Ratio|ANAB - Business Payback Period|Price to Earnings Ratio ATXS|ENGN: Company Value to Net Income|Price to Earnings Ratio RAPT Therapeutics (RAPT)|JBIO (Aerovate) - Company Value to Net Income|P/E Multiple ACRS (Aclaris Therapeutics)|Company Value to Net Income KYTX|Tiziana Life Sciences - P/E Multiple|CABA: Price to Earnings Ratio|VTYX: P/E Multiple|THTX (Theratechnologies, Inc) - Price to Earnings Ratio|AVTX (Avalo Therapeutics, Inc.) - P/E Multiple|P/E Multiple Eledon Pharmaceuticals|Price to Earnings Ratio Agenus Inc. (AGEN)|Price to Earnings Ratio Climb Bio Inc. CLYM|P/E Multiple ZURA (Zura Bio Ltd)|ATYR - Price to Earnings Ratio|ADAG - Price to Earnings Ratio|IMA - P/E Multiple|STTK: P/E Multiple|Equillium Bio (EQ) - P/E Multiple|CNTB (connectbiopharm.com) - P/E Multiple|IMUX: Company Value to Net Income|P/E Multiple ATRA|P/E Multiple InflaRx NV (IFRX)|X4 Pharmaceuticals, Inc. (XFOR) - Market Cap to Net Income|P/E Multiple adicetbio.com ACET|Celularity - P/E Multiple|Company Value to Net Income INMB (INmune Bio Corp)|BRNS (Barinthus Bio) - Price to Earnings Ratio|Market Cap to Net Income KZR (Kezar Life Sciences)|Price to Earnings Ratio SAB Biotherapeutics Inc.|Akari Therapeutics Plc - Market Cap to Net Income|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd.)|Price to Earnings Ratio Q32 Bio Inc QTTB|Price to Earnings Ratio geovax.com GOVX|P/E Multiple edesabiotech.com EDSA|iBio Corporation - P/E Multiple|Company Value to Net Income CARM (carismatx.com)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Bolt Bio (BOLT) - P/E Multiple|HCWB (HCW Biologics Inc) - P/E Multiple|Price to Earnings Ratio Aptevo Therapeutics (APVO)|P/E Multiple AIM|Market Price to Net Income Ratio ADTX|P/E Multiple GRI (GRI Bio Corporation)|P/E Multiple XORTX Corp XRTX|HIND - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|INDP (Indaptus Therapeutics, Inc.) - Price to Earnings Ratio|Scinai Immunotherapeutics Ltd (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple